SG11201706028RA - Cenicriviroc for the treatment of fibrosis - Google Patents
Cenicriviroc for the treatment of fibrosisInfo
- Publication number
- SG11201706028RA SG11201706028RA SG11201706028RA SG11201706028RA SG11201706028RA SG 11201706028R A SG11201706028R A SG 11201706028RA SG 11201706028R A SG11201706028R A SG 11201706028RA SG 11201706028R A SG11201706028R A SG 11201706028RA SG 11201706028R A SG11201706028R A SG 11201706028RA
- Authority
- SG
- Singapore
- Prior art keywords
- cenicriviroc
- fibrosis
- treatment
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 title 1
- 229950011033 cenicriviroc Drugs 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114304P | 2015-02-10 | 2015-02-10 | |
| PCT/US2015/051467 WO2016130179A1 (en) | 2015-02-10 | 2015-09-22 | Cenicriviroc for the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706028RA true SG11201706028RA (en) | 2017-08-30 |
Family
ID=56614560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706028RA SG11201706028RA (en) | 2015-02-10 | 2015-09-22 | Cenicriviroc for the treatment of fibrosis |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20180110754A1 (enExample) |
| EP (1) | EP3256124B1 (enExample) |
| JP (2) | JP6676660B2 (enExample) |
| KR (1) | KR20170113596A (enExample) |
| CN (1) | CN107405403B (enExample) |
| AU (1) | AU2015382376B2 (enExample) |
| BR (1) | BR112017016388A2 (enExample) |
| CA (1) | CA2975445A1 (enExample) |
| ES (1) | ES2864767T3 (enExample) |
| HK (1) | HK1247558A1 (enExample) |
| IL (1) | IL253617A0 (enExample) |
| MX (1) | MX2017010277A (enExample) |
| RU (1) | RU2722641C2 (enExample) |
| SG (1) | SG11201706028RA (enExample) |
| WO (1) | WO2016130179A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003014105A1 (en) | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use as hiv inhibitors |
| US10526349B2 (en) | 2014-12-23 | 2020-01-07 | Tobira Therapeutics, Inc. | Process of making cenicriviroc and related analogs |
| MX2018015871A (es) | 2016-06-21 | 2019-08-14 | Tobira Therapeutics Inc | Cenicriviroc purificado e intermedios purificados para fabricar cenicriviroc. |
| WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞，其制备方法及抗纤维化的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2249027A (en) * | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
| WO2003014105A1 (en) | 2001-08-08 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use as hiv inhibitors |
| WO2006059716A1 (ja) | 2004-12-03 | 2006-06-08 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| JP6178788B2 (ja) * | 2011-06-27 | 2017-08-09 | ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） | Ｃｃｒ２アンタゴニストペプチド |
| JP6263815B2 (ja) * | 2013-03-05 | 2018-01-24 | 国立大学法人 岡山大学 | 細胞死抑制剤及びその製造方法 |
| JP6391674B2 (ja) * | 2013-05-15 | 2018-09-19 | トビラ セラピューティクス， インコーポレイテッド | セニクリビロック組成物並びにその製造及び使用方法 |
| KR101669124B1 (ko) * | 2013-07-11 | 2016-10-25 | 서울대학교병원 | 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물 |
-
2015
- 2015-09-22 US US15/549,958 patent/US20180110754A1/en not_active Abandoned
- 2015-09-22 ES ES15882259T patent/ES2864767T3/es active Active
- 2015-09-22 HK HK18106984.5A patent/HK1247558A1/zh unknown
- 2015-09-22 RU RU2017130289A patent/RU2722641C2/ru active
- 2015-09-22 BR BR112017016388-8A patent/BR112017016388A2/pt not_active Application Discontinuation
- 2015-09-22 EP EP15882259.3A patent/EP3256124B1/en not_active Not-in-force
- 2015-09-22 MX MX2017010277A patent/MX2017010277A/es unknown
- 2015-09-22 CN CN201580076576.9A patent/CN107405403B/zh not_active Expired - Fee Related
- 2015-09-22 KR KR1020177023821A patent/KR20170113596A/ko not_active Ceased
- 2015-09-22 JP JP2017560462A patent/JP6676660B2/ja not_active Expired - Fee Related
- 2015-09-22 AU AU2015382376A patent/AU2015382376B2/en not_active Expired - Fee Related
- 2015-09-22 CA CA2975445A patent/CA2975445A1/en not_active Abandoned
- 2015-09-22 WO PCT/US2015/051467 patent/WO2016130179A1/en not_active Ceased
- 2015-09-22 SG SG11201706028RA patent/SG11201706028RA/en unknown
-
2017
- 2017-07-23 IL IL253617A patent/IL253617A0/en unknown
-
2019
- 2019-02-26 US US16/285,867 patent/US20190343806A1/en not_active Abandoned
-
2020
- 2020-03-12 JP JP2020042730A patent/JP2020111586A/ja active Pending
- 2020-06-03 US US16/891,979 patent/US20200360347A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015382376A1 (en) | 2017-08-17 |
| KR20170113596A (ko) | 2017-10-12 |
| US20180110754A1 (en) | 2018-04-26 |
| BR112017016388A2 (pt) | 2018-03-27 |
| RU2722641C2 (ru) | 2020-06-02 |
| AU2015382376B2 (en) | 2021-07-01 |
| EP3256124A4 (en) | 2018-09-26 |
| MX2017010277A (es) | 2017-12-07 |
| JP6676660B2 (ja) | 2020-04-08 |
| RU2017130289A3 (enExample) | 2019-04-22 |
| US20190343806A1 (en) | 2019-11-14 |
| HK1247558A1 (zh) | 2018-09-28 |
| RU2017130289A (ru) | 2019-03-12 |
| EP3256124A1 (en) | 2017-12-20 |
| ES2864767T3 (es) | 2021-10-14 |
| CN107405403B (zh) | 2021-04-20 |
| JP2020111586A (ja) | 2020-07-27 |
| EP3256124B1 (en) | 2020-12-23 |
| CA2975445A1 (en) | 2016-08-18 |
| CN107405403A (zh) | 2017-11-28 |
| WO2016130179A1 (en) | 2016-08-18 |
| JP2018505218A (ja) | 2018-02-22 |
| US20200360347A1 (en) | 2020-11-19 |
| IL253617A0 (en) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201803727B (en) | Treatment of fibrosis | |
| IL258002A (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| IL247515A0 (en) | Snekribirock for the treatment of leprosy | |
| IL266530A (en) | Fibrosis treatment | |
| IL250960A0 (en) | Combined treatment of sinecriviroc for the treatment of leprosy | |
| GB201502137D0 (en) | Treatment | |
| PL3524255T3 (pl) | Kompozycja do leczenia trądziku | |
| GB201608885D0 (en) | Treatment | |
| GB201522243D0 (en) | Treatment | |
| IL257908A (en) | Methods for the treatment of epilepsy | |
| IL253617A0 (en) | Snekribirock for the treatment of leprosy | |
| IL258137B1 (en) | HIV treatment measures | |
| GB201519450D0 (en) | Novel treatment | |
| GB201508841D0 (en) | Treatment | |
| GB201503008D0 (en) | Treatment | |
| PL2937084T3 (pl) | Sposób leczenia hipercholesterolemii | |
| GB201407806D0 (en) | Treatment of fibrosis | |
| GB201617107D0 (en) | Treatment | |
| AU2015900903A0 (en) | Treatment for fibrosis | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment | |
| HK1241278A1 (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| GB201518349D0 (en) | Treatment | |
| GB201609683D0 (en) | Treatment | |
| GB201515739D0 (en) | Treatment |